Does the media refer more to LEGN or JANX?

In the previous week, Legend Biotech had 12 more articles in the media than Janux Therapeutics. MarketBeat recorded 32 mentions for Legend Biotech and 20 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.43 beat Legend Biotech's score of 0.29 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 5 Very Positive mention(s) 4 Positive mention(s) 13 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Janux Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VCYT or JANX?

In the previous week, Janux Therapeutics had 13 more articles in the media than Veracyte. MarketBeat recorded 20 mentions for Janux Therapeutics and 7 mentions for Veracyte. Veracyte's average media sentiment score of 1.40 beat Janux Therapeutics' score of 0.43 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor JANX or RCUS?

In the previous week, Janux Therapeutics had 5 more articles in the media than Arcus Biosciences. MarketBeat recorded 20 mentions for Janux Therapeutics and 15 mentions for Arcus Biosciences. Janux Therapeutics' average media sentiment score of 0.43 beat Arcus Biosciences' score of 0.38 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Arcus Biosciences 1 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is ALMS or JANX more profitable?

Janux Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Janux Therapeutics' return on equity of -11.89% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -5,933.46% -95.08% -75.81% Janux Therapeutics N/A -11.89% -11.13%

Does the media favor ALMS or JANX?

In the previous week, Janux Therapeutics had 6 more articles in the media than Alumis. MarketBeat recorded 20 mentions for Janux Therapeutics and 14 mentions for Alumis. Janux Therapeutics' average media sentiment score of 0.43 beat Alumis' score of 0.33 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Janux Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GMTX or JANX?

Janux Therapeutics has a consensus target price of $37.58, suggesting a potential upside of 133.15%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Janux Therapeutics 2 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is GMTX or JANX more profitable?

Janux Therapeutics' return on equity of -11.89% beat Gemini Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gemini Therapeutics N/A -38.78% -35.88% Janux Therapeutics N/A -11.89% -11.13%

Janux Therapeutics (JANX) Competitors

$16.12 +0.12 (+0.75%)

Closing price 04:00 PM Eastern

Extended Trading

$16.12 0.00 (0.00%)

As of 07:56 PM Eastern

Compare

JANX vs. LEGN, VCYT, RCUS, ALMS, and GMTX

Should you buy Janux Therapeutics stock or one of its competitors? Janux Therapeutics's main competitors and comparable companies include Legend Biotech (LEGN), Veracyte (VCYT), Arcus Biosciences (RCUS), Alumis (ALMS), and Gemini Therapeutics (GMTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Janux Therapeutics compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Janux Therapeutics (NASDAQ:JANX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Janux Therapeutics has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.68	-$296.80M	-$0.68	N/A
Janux Therapeutics	$10M	98.56	-$113.62M	-$1.64	N/A

Janux Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
Janux Therapeutics	N/A	-11.89%	-11.13%

Legend Biotech currently has a consensus target price of $52.29, suggesting a potential upside of 156.68%. Janux Therapeutics has a consensus target price of $37.58, suggesting a potential upside of 133.15%. Given Legend Biotech's higher possible upside, analysts plainly believe Legend Biotech is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50

Legend Biotech has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market.

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Legend Biotech had 12 more articles in the media than Janux Therapeutics. MarketBeat recorded 32 mentions for Legend Biotech and 20 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.43 beat Legend Biotech's score of 0.29 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	5 Very Positive mention(s)	4 Positive mention(s)	13 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Janux Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Janux Therapeutics beats Legend Biotech on 10 of the 16 factors compared between the two stocks.

How does Janux Therapeutics compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Janux Therapeutics (NASDAQ:JANX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Veracyte has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.5, meaning that its share price is 150% more volatile than the broader market.

Veracyte has a net margin of 20.37% compared to Janux Therapeutics' net margin of 0.00%. Veracyte's return on equity of 9.26% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Janux Therapeutics	N/A	-11.89%	-11.13%

Veracyte has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	6.41	$66.35M	$1.41	29.26
Janux Therapeutics	$10M	98.56	-$113.62M	-$1.64	N/A

75.4% of Janux Therapeutics shares are owned by institutional investors. 1.6% of Veracyte shares are owned by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Veracyte currently has a consensus price target of $54.33, indicating a potential upside of 31.72%. Janux Therapeutics has a consensus price target of $37.58, indicating a potential upside of 133.15%. Given Janux Therapeutics' higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Janux Therapeutics had 13 more articles in the media than Veracyte. MarketBeat recorded 20 mentions for Janux Therapeutics and 7 mentions for Veracyte. Veracyte's average media sentiment score of 1.40 beat Janux Therapeutics' score of 0.43 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Janux Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Veracyte beats Janux Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Janux Therapeutics compare to Arcus Biosciences?

Janux Therapeutics (NASDAQ:JANX) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Janux Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -393.16%. Janux Therapeutics' return on equity of -11.89% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Arcus Biosciences	-393.16%	-89.54%	-45.61%

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Janux Therapeutics presently has a consensus target price of $37.58, suggesting a potential upside of 133.15%. Arcus Biosciences has a consensus target price of $37.80, suggesting a potential upside of 28.15%. Given Janux Therapeutics' higher probable upside, analysts plainly believe Janux Therapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Janux Therapeutics has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

Janux Therapeutics has higher earnings, but lower revenue than Arcus Biosciences. Janux Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	98.56	-$113.62M	-$1.64	N/A
Arcus Biosciences	$247M	15.21	-$353M	-$3.90	N/A

In the previous week, Janux Therapeutics had 5 more articles in the media than Arcus Biosciences. MarketBeat recorded 20 mentions for Janux Therapeutics and 15 mentions for Arcus Biosciences. Janux Therapeutics' average media sentiment score of 0.43 beat Arcus Biosciences' score of 0.38 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcus Biosciences	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Janux Therapeutics beats Arcus Biosciences on 12 of the 16 factors compared between the two stocks.

How does Janux Therapeutics compare to Alumis?

Alumis (NASDAQ:ALMS) and Janux Therapeutics (NASDAQ:JANX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

75.4% of Janux Therapeutics shares are held by institutional investors. 33.7% of Alumis shares are held by insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Janux Therapeutics had 6 more articles in the media than Alumis. MarketBeat recorded 20 mentions for Janux Therapeutics and 14 mentions for Alumis. Janux Therapeutics' average media sentiment score of 0.43 beat Alumis' score of 0.33 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Janux Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alumis currently has a consensus price target of $40.30, suggesting a potential upside of 59.23%. Janux Therapeutics has a consensus price target of $37.58, suggesting a potential upside of 133.15%. Given Janux Therapeutics' higher possible upside, analysts plainly believe Janux Therapeutics is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50

Alumis has a beta of -0.69, suggesting that its stock price is 169% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market.

Janux Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Janux Therapeutics' return on equity of -11.89% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-95.08%	-75.81%
Janux Therapeutics	N/A	-11.89%	-11.13%

Janux Therapeutics has lower revenue, but higher earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	134.17	-$243.32M	-$1.98	N/A
Janux Therapeutics	$10M	98.56	-$113.62M	-$1.64	N/A

Summary

Janux Therapeutics beats Alumis on 10 of the 16 factors compared between the two stocks.

How does Janux Therapeutics compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Janux Therapeutics (NASDAQ:JANX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.5, indicating that its stock price is 150% more volatile than the broader market.

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Janux Therapeutics has a consensus target price of $37.58, suggesting a potential upside of 133.15%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50

Janux Therapeutics' return on equity of -11.89% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Janux Therapeutics	N/A	-11.89%	-11.13%

Gemini Therapeutics has higher earnings, but lower revenue than Janux Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Janux Therapeutics	$10M	98.56	-$113.62M	-$1.64	N/A

In the previous week, Janux Therapeutics had 20 more articles in the media than Gemini Therapeutics. MarketBeat recorded 20 mentions for Janux Therapeutics and 0 mentions for Gemini Therapeutics. Janux Therapeutics' average media sentiment score of 0.43 beat Gemini Therapeutics' score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Janux Therapeutics	Neutral

Summary

Janux Therapeutics beats Gemini Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Janux Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JANX vs. The Competition

Export

Metric	Janux Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$978.19M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-9.83	10.67	269.06	25.28
Price / Sales	98.56	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	1.06	16.78	12.91	6.24
Net Income	-$113.62M	-$13.32M	$3.45B	$347.60M
7 Day Performance	1.70%	1.74%	1.12%	1.07%
1 Month Performance	2.15%	1.60%	1.79%	1.03%
1 Year Performance	-35.44%	56.43%	67.69%	20.77%

Janux Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JANX Janux Therapeutics	2.6867 of 5 stars	$16.12 +0.8%	$37.58 +133.1%	-35.9%	$978.19M	$10M	N/A	30	News Coverage Analyst Revision
LEGN Legend Biotech	3.0778 of 5 stars	$20.66 -0.4%	$55.29 +167.6%	-45.1%	$3.85B	$1.03B	N/A	2,965	News Coverage Earnings Report Analyst Forecast
VCYT Veracyte	4.4689 of 5 stars	$46.27 -2.0%	$54.33 +17.4%	+38.9%	$3.80B	$517.15M	32.82	790	Positive News Analyst Upgrade
RCUS Arcus Biosciences	2.7375 of 5 stars	$28.68 +0.2%	$37.80 +31.8%	+186.7%	$3.64B	$247M	N/A	500
ALMS Alumis	3.6664 of 5 stars	$27.53 -0.3%	$40.30 +46.4%	+452.3%	$3.52B	$24.05M	N/A	N/A	Earnings Report Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JANX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Janux Therapeutics (JANX) Competitors

JANX vs. LEGN, VCYT, RCUS, ALMS, and GMTX

How does Janux Therapeutics compare to Legend Biotech?

Summary

How does Janux Therapeutics compare to Veracyte?

Summary

How does Janux Therapeutics compare to Arcus Biosciences?

Summary

How does Janux Therapeutics compare to Alumis?

Summary

How does Janux Therapeutics compare to Gemini Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX vs. The Competition

Janux Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Janux Therapeutics (JANX) Competitors

JANX vs. LEGN, VCYT, RCUS, ALMS, and GMTX

How does Janux Therapeutics compare to Legend Biotech?

Which has better earnings & valuation, LEGN or JANX?

Is LEGN or JANX more profitable?

Do analysts rate LEGN or JANX?

Which has more risk and volatility, LEGN or JANX?

Do institutionals and insiders have more ownership in LEGN or JANX?

Does the media refer more to LEGN or JANX?

Summary

How does Janux Therapeutics compare to Veracyte?

Which has more risk and volatility, VCYT or JANX?

Is VCYT or JANX more profitable?

Which has higher earnings and valuation, VCYT or JANX?

Do institutionals & insiders believe in VCYT or JANX?

Do analysts prefer VCYT or JANX?

Does the media refer more to VCYT or JANX?

Summary

How does Janux Therapeutics compare to Arcus Biosciences?

Is JANX or RCUS more profitable?

Do institutionals & insiders hold more shares of JANX or RCUS?

Do analysts prefer JANX or RCUS?

Which has more volatility & risk, JANX or RCUS?

Which has preferable valuation and earnings, JANX or RCUS?

Does the media favor JANX or RCUS?

Summary

How does Janux Therapeutics compare to Alumis?

Do insiders & institutionals hold more shares of ALMS or JANX?

Does the media favor ALMS or JANX?

Do analysts prefer ALMS or JANX?

Which has more risk and volatility, ALMS or JANX?

Is ALMS or JANX more profitable?

Which has stronger earnings & valuation, ALMS or JANX?

Summary

How does Janux Therapeutics compare to Gemini Therapeutics?

Which has more risk and volatility, GMTX or JANX?

Do insiders and institutionals have more ownership in GMTX or JANX?

Do analysts recommend GMTX or JANX?

Is GMTX or JANX more profitable?

Which has higher valuation and earnings, GMTX or JANX?

Does the media refer more to GMTX or JANX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX vs. The Competition

Janux Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools